CVS Health (NYSE:CVS) Raised to Overweight at Cantor Fitzgerald

CVS Health (NYSE:CVS) was upgraded by analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued on Wednesday, Marketbeat Ratings reports.

CVS has been the subject of several other reports. StockNews.com downgraded CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Truist Financial cut their target price on CVS Health from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research note on Tuesday, December 3rd. Finally, Wells Fargo & Company raised CVS Health from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $60.00 to $66.00 in a research note on Monday, November 18th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.28.

CVS Health Trading Up 4.9 %

Shares of NYSE:CVS opened at $66.35 on Wednesday. CVS Health has a 1 year low of $43.56 and a 1 year high of $80.75. The firm has a market capitalization of $83.49 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 0.60 and a beta of 0.61. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The business’s 50 day moving average price is $50.71 and its 200-day moving average price is $55.94.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. On average, equities research analysts forecast that CVS Health will post 5.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CVS Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Integrated Advisors Network LLC boosted its stake in shares of CVS Health by 0.7% in the 3rd quarter. Integrated Advisors Network LLC now owns 27,625 shares of the pharmacy operator’s stock valued at $1,737,000 after buying an additional 200 shares during the period. Widmann Financial Services Inc. boosted its stake in shares of CVS Health by 1.8% in the 3rd quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator’s stock valued at $724,000 after buying an additional 200 shares during the period. EagleClaw Capital Managment LLC boosted its stake in shares of CVS Health by 3.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock valued at $275,000 after buying an additional 200 shares during the period. DT Investment Partners LLC boosted its stake in shares of CVS Health by 7.8% in the 3rd quarter. DT Investment Partners LLC now owns 2,777 shares of the pharmacy operator’s stock valued at $175,000 after buying an additional 202 shares during the period. Finally, Manchester Capital Management LLC boosted its stake in shares of CVS Health by 4.8% in the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock valued at $200,000 after buying an additional 204 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.